The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802).
Mitsuhisa Takatsuki
No relevant relationships to disclose
Susumu Eguchi
No relevant relationships to disclose
Shoji Tokunaga
No relevant relationships to disclose
Yasunori Emi
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Shinji Uchida
No relevant relationships to disclose
Masahiko Sakoda
No relevant relationships to disclose
Yoshihiro Kakeji
No relevant relationships to disclose
Ken Shirabe
No relevant relationships to disclose
Yoshito Akagi
No relevant relationships to disclose
Toru Beppu
No relevant relationships to disclose
Hideo Baba
No relevant relationships to disclose
Shinichi Ueno
No relevant relationships to disclose
Shoji Natsugoe
No relevant relationships to disclose
Yutaka Ogata
No relevant relationships to disclose
Yoshihiko Maehara
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha